Astellas Pharma

Type
Offshoring/Delocalisation
Country
Netherlands
Region
West-Nederland; Zuid-Holland; Agglomeratie Leiden en Bollenstreek
Location of affected unit(s)
Leiden
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.10 - Manufacture of basic pharmaceutical products
New offshoring locations
United States of America, Japan
200 jobs
Number of planned job losses
Job loss
Announcement Date
2 June 2017
Employment effect (start)
Foreseen end date

Description

The Japan-owned Astellas Pharma announced in June 2017 that it will relocate its development and testing of medicines from Leiden, Zuid-Holland to Northbrook in the US and Tokyo in Japan, which will result in the loss of at the least 200 jobs in the Netherlands. The company has stated that Leiden will remain a regional centre that will undertake support activities, such as quality control, supply chain management and more. 

As of June 2017, Astellas Pharma employs approximately 550 people in Leiden. 

Sources

  • 2 June 2017: Het Financieel Dagblad

Citation

Eurofound (2017), Astellas Pharma, Offshoring/Delocalisation in Netherlands, factsheet number 92903, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/92903.